IP Library Granted Patent US 7,932,371
Granted Patent B2
US 7,932,371 · App. 12/200,456 · Granted Apr 26, 2011

Tick octopamine receptor nucleic acid molecules

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,932,371
App. No.
12/200,456
Granted
Apr 26, 2011
Kind
B2
Abstract

The present invention relates to tick octopamine receptor nucleic acid molecules; to tick octopamine receptor proteins encoded by such nucleic acid molecules; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes inhibitory compounds, particularly those that specifically inhibit tick octopamine receptor activity, as well as the use of such compounds to treat animals.

Claims (11)

1. An isolated nucleic acid molecule selected from the group consisting of:

(a) a nucleic acid molecule comprising a nucleic acid sequence that encodes a protein comprising SEQ ID NO:40; and

(b) a nucleic acid molecule comprising a nucleic acid sequence fully complementary to the nucleic acid sequence of (a).

2. A recombinant molecule comprising a nucleic acid molecule as set forth in claim 1 operatively linked to a transcription control sequence.

3. A recombinant virus comprising a nucleic acid molecule as set forth in claim 1 .

4. An isolated, recombinant cell comprising a nucleic acid molecule as set forth in claim 1 .

5. The isolated nucleic acid molecule of claim 1 , wherein said nucleic acid sequence is selected from the group consisting of SEQ ID NO:39 and SEQ ID NO:41.

6. An isolated nucleic acid molecule consisting of a nucleic acid sequence selected from the group consisting of:

(a) a nucleic acid sequence that encodes a polypeptide consisting of SEQ ID NO: 34, SEQ ID NO:37 or SEQ ID NO:40; and

(b) a nucleic acid sequence fully complementary to the nucleic acid sequence of (a).

7. The isolated nucleic acid molecule of claim 6 , wherein said nucleic acid sequence is selected from the group consisting of SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 39 and SEQ ID NO: 41.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Dec 14, 2023
From: JPMORGAN CHASE BANK, N.A.
To: HESKA CORPORATION; DIAMOND ANIMAL HEALTH, INC.; HESKA IMAGING, LLC
Reel/Frame 066012/0887 →
SECURITY INTEREST Recorded Oct 24, 2017
From: HESKA CORPORATION; DIAMOND ANIMAL HEALTH, INC.; HESKA IMAGING, LLC
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 044636/0972 →
SECURITY AGREEMENT Recorded Feb 26, 2009
From: HESKA CORPORATION
To: WELLS FARGO BUSINESS CREDIT, INC.
Reel/Frame 022354/0170 →